NASDAQ:ACAD
$18.57
(
-0.482%
)
Friday, 27th Jan 2023
ACADIA Pharmaceuticals Inc. Stock Price (Quote)
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $15.08 | $19.74 | Friday, 27th Jan 2023 ACAD stock ended at $18.57. This is 0.482% less than the trading day before Thursday, 26th Jan 2023. During the day the stock fluctuated 2.09% from a day low at $18.39 to a day high of $18.77. |
| 90 days | $13.73 | $19.74 | |
| 52 weeks | $12.24 | $28.06 |
Historical ACADIA Pharmaceuticals Inc. prices
| Date | Open | High | Low | Close | Volume |
| 2023-01-27 | $18.57 | $18.77 | $18.39 | $18.57 | 935 237 |
| 2023-01-26 | $18.79 | $18.96 | $18.40 | $18.66 | 1 382 452 |
| 2023-01-25 | $18.85 | $19.18 | $18.40 | $18.69 | 943 686 |
| 2023-01-24 | $19.01 | $19.54 | $18.88 | $19.00 | 915 168 |
| 2023-01-23 | $19.38 | $19.74 | $18.96 | $19.09 | 2 509 673 |
| 2023-01-20 | $18.67 | $19.38 | $18.53 | $19.35 | 1 988 084 |
| 2023-01-19 | $17.85 | $18.50 | $17.85 | $18.48 | 968 800 |
| 2023-01-18 | $18.12 | $18.49 | $17.89 | $17.97 | 1 276 713 |
| 2023-01-17 | $18.28 | $18.33 | $17.76 | $18.05 | 1 044 429 |
| 2023-01-13 | $18.15 | $18.77 | $18.15 | $18.40 | 1 592 004 |
| 2023-01-12 | $17.03 | $18.39 | $16.82 | $18.34 | 1 536 414 |
| 2023-01-11 | $17.22 | $17.22 | $16.74 | $17.02 | 891 600 |
| 2023-01-10 | $16.86 | $17.45 | $16.78 | $17.30 | 950 000 |
| 2023-01-09 | $17.13 | $17.22 | $16.70 | $16.86 | 1 365 800 |
| 2023-01-06 | $17.37 | $17.57 | $17.04 | $17.30 | 1 261 500 |
| 2023-01-05 | $17.00 | $17.27 | $16.76 | $17.22 | 836 069 |
| 2023-01-04 | $16.40 | $17.12 | $16.40 | $17.10 | 1 317 193 |
| 2023-01-03 | $16.55 | $16.70 | $15.77 | $16.32 | 1 030 245 |
| 2022-12-30 | $15.80 | $15.98 | $15.54 | $15.92 | 814 128 |
| 2022-12-29 | $15.44 | $16.20 | $15.25 | $15.95 | 1 005 254 |
| 2022-12-28 | $15.33 | $15.71 | $15.08 | $15.28 | 714 677 |
| 2022-12-27 | $15.51 | $15.61 | $15.26 | $15.30 | 699 577 |
| 2022-12-23 | $15.74 | $15.83 | $15.37 | $15.47 | 1 435 038 |
| 2022-12-22 | $15.16 | $15.83 | $15.06 | $15.82 | 1 356 795 |
| 2022-12-21 | $15.47 | $15.66 | $15.10 | $15.31 | 1 155 168 |
| 2022-12-20 | $15.00 | $15.55 | $14.80 | $15.45 | 936 642 |
| 2022-12-19 | $15.39 | $15.48 | $14.88 | $15.10 | 1 054 931 |
| 2022-12-16 | $14.93 | $15.50 | $14.87 | $15.39 | 1 819 848 |
| 2022-12-15 | $15.63 | $15.75 | $14.91 | $15.07 | 1 256 697 |
| 2022-12-14 | $15.70 | $16.13 | $15.48 | $15.78 | 1 053 612 |
| 2022-12-13 | $15.79 | $16.04 | $15.44 | $15.82 | 1 274 728 |
| 2022-12-12 | $14.53 | $15.66 | $14.48 | $15.51 | 1 451 863 |
| 2022-12-09 | $14.59 | $14.73 | $14.48 | $14.49 | 1 083 774 |
| 2022-12-08 | $14.72 | $14.84 | $14.45 | $14.63 | 859 676 |
| 2022-12-07 | $14.93 | $15.06 | $14.66 | $14.66 | 600 431 |
| 2022-12-06 | $15.17 | $15.19 | $14.79 | $14.90 | 883 161 |
| 2022-12-05 | $15.62 | $15.63 | $15.06 | $15.24 | 1 083 058 |
| 2022-12-02 | $15.18 | $15.91 | $15.06 | $15.76 | 720 985 |
| 2022-12-01 | $15.60 | $15.75 | $15.07 | $15.34 | 815 294 |
| 2022-11-30 | $14.75 | $15.59 | $14.65 | $15.58 | 1 308 959 |
| 2022-11-29 | $14.72 | $14.92 | $14.56 | $14.67 | 1 144 884 |
| 2022-11-28 | $15.00 | $15.14 | $14.70 | $14.77 | 1 098 900 |
| 2022-11-25 | $15.04 | $15.54 | $14.99 | $15.11 | 316 898 |
| 2022-11-23 | $14.99 | $15.26 | $14.68 | $15.00 | 788 967 |
| 2022-11-22 | $14.90 | $15.12 | $14.62 | $15.04 | 772 963 |
| 2022-11-21 | $15.27 | $15.27 | $14.69 | $14.70 | 343 884 |
| 2022-11-18 | $15.31 | $15.42 | $15.00 | $15.14 | 359 119 |
| 2022-11-17 | $15.07 | $15.12 | $14.80 | $14.81 | 377 148 |
| 2022-11-16 | $15.76 | $15.82 | $15.16 | $15.26 | 509 804 |
| 2022-11-15 | $16.31 | $16.44 | $15.33 | $15.68 | 598 934 |
About ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psych... ACAD Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
